🇺🇸 FDA
Patent

US 8344126

Compositions and methods for inhibiting expression of XBP-1 gene

granted A61PA61P35/00

Quick answer

US patent 8344126 (Compositions and methods for inhibiting expression of XBP-1 gene) held by Alnylam Pharmaceuticals, Inc. expires Mon Dec 27 2032 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Alnylam Pharmaceuticals, Inc.
Grant date
Tue Jan 01 2013 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Dec 27 2032 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
12
CPC classes
A61P, A61P35/00